[{"id":"26110bab-e520-4fd5-a132-37b6e59b26a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03801434","created_at":"2021-01-18T18:47:30.564Z","updated_at":"2024-07-02T16:35:30.623Z","phase":"Phase 2","brief_title":"Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders","source_id_and_acronym":"NCT03801434","lead_sponsor":"William Shomali","biomarkers":" JAK2 • ETV6 • PCM1","pipe":" | ","alterations":" JAK2 mutation • JAK2 rearrangement","tags":["JAK2 • ETV6 • PCM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 mutation • JAK2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 11/15/2019","start_date":" 11/15/2019","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2023-11-02"},{"id":"34bea2f2-8a1e-4060-9d83-36b2c4268cbc","acronym":"Study 0314","url":"https://clinicaltrials.gov/study/NCT02268253","created_at":"2021-01-18T10:39:50.644Z","updated_at":"2024-07-02T16:35:52.835Z","phase":"Phase 2","brief_title":"Tagraxofusp (SL-401) in Patients With CMML or MF","source_id_and_acronym":"NCT02268253 - Study 0314","lead_sponsor":"Stemline Therapeutics, Inc.","biomarkers":" PDGFRA • JAK2 • PDGFRB • PCM1","pipe":" | ","alterations":" FGFR1 rearrangement","tags":["PDGFRA • JAK2 • PDGFRB • PCM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Elzonris (tagraxofusp-erzs)"],"overall_status":"Completed","enrollment":" Enrollment 82","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 03/07/2023","primary_completion_date":" 03/07/2023","study_txt":" Completion: 03/07/2023","study_completion_date":" 03/07/2023","last_update_posted":"2023-03-21"},{"id":"30869735-a511-4b8a-aed0-58cf67b563b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03943394","created_at":"2021-01-18T19:25:01.944Z","updated_at":"2024-07-02T16:36:59.769Z","phase":"","brief_title":"PCM1-JAK2 in Therapy Related Neoplasms","source_id_and_acronym":"NCT03943394","lead_sponsor":"Assiut University","biomarkers":" JAK2 • PCM1","pipe":" | ","alterations":" PCM1-JAK2 fusion • JAK2 fusion • PCM1-JAK2 fusion","tags":["JAK2 • PCM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PCM1-JAK2 fusion • JAK2 fusion • PCM1-JAK2 fusion"],"overall_status":"Unknown status","enrollment":" Enrollment 140","initiation":"Initiation: 06/01/2019","start_date":" 06/01/2019","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/01/2022","study_completion_date":" 06/01/2022","last_update_posted":"2019-05-09"}]